enGene Announced Preliminary Data From LEGEND Study Of Detalimogene Voraplasmid (EG-70) In Bacillus Calmette-guérin-unresponsive, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ, Showing Complete Response Rate At Any Time Of 71%
Portfolio Pulse from Benzinga Newsdesk
enGene announced preliminary data from the LEGEND study of Detalimogene Voraplasmid (EG-70) in treating Bacillus Calmette-Guérin-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ, showing a complete response rate of 71%.
September 26, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
enGene's preliminary data from the LEGEND study shows a 71% complete response rate for EG-70 in treating a specific type of bladder cancer, which could positively impact the company's stock price.
The high complete response rate of 71% in the LEGEND study is a significant positive outcome for enGene's EG-70, indicating potential effectiveness in treating bladder cancer. This could lead to increased investor confidence and a positive impact on ENGN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100